These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33975993)

  • 1. Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial.
    Singh I; Jose V; Patel R; Arora S
    Indian J Pharmacol; 2021; 53(1):6-12. PubMed ID: 33975993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.
    Jeka S; Dokoupilová E; Kivitz A; Żuchowski P; Vogg B; Krivtsova N; Sekhar S; Banerjee S; Schwebig A; Poetzl J; Body JJ; Eastell R
    J Bone Miner Res; 2024 Apr; 39(3):202-210. PubMed ID: 38477751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.
    Jamshidi A; Vojdanian M; Soroush M; Akbarian M; Aghaei M; Hajiabbasi A; Mirfeizi Z; Khabbazi A; Alishiri G; Haghighi A; Salimzadeh A; Karimzadeh H; Shirani F; Fard MRH; Nazarinia M; Soroosh S; Anjidani N; Gharibdoost F
    Arthritis Res Ther; 2022 Jun; 24(1):161. PubMed ID: 35773713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
    Hagino H; Narita R; Yokoyama Y; Watanabe M; Tomomitsu M
    Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis.
    Jiang Y; Huo Y; Li Y; Kong X; Wang B; Liu F; Zheng X; Li Y; Yang Y; Xu Y; Xue Q; Hu Z; Xiao Y; Ma W; Guo Y; Yu W; Xia W
    Expert Opin Biol Ther; 2024 Jul; 24(7):665-672. PubMed ID: 38752402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk.
    Zhang H; Gu JM; Chao AJ; Cheng Q; Teng DH; Yu JM; Wang BW; Huo YN; Mao L; Zhang Q; Yang H; Yan SG; Zhang KQ; Zhao XL; Lin H; Pei Y; Yuan Z; Dai RC; He L; Chen L; Su YF; Deng ZL; You L; Ban B; Zhu M; Cao YL; Zhu YK; Li ZJ; Zhang Z; Yi CQ; Lu YB; Wang G; Han CC; Wang ZJ; Li XX; Zhang ZL
    Acta Pharmacol Sin; 2023 Feb; 44(2):446-453. PubMed ID: 35896694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension.
    Koh JM; Chung DJ; Chung YS; Kang MI; Kim IJ; Min YK; Oh HJ; Park IH; Lee YS; Kravitz B; Waterhouse B; Nino A; Fitzpatrick LA
    Yonsei Med J; 2016 Jul; 57(4):905-14. PubMed ID: 27189284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects.
    Zhang H; Li C; Liu J; Wu M; Li X; Zhu X; Li Q; Wang B; Mao Y; Ding Y; Jin Q
    Expert Opin Investig Drugs; 2021 Feb; 30(2):185-192. PubMed ID: 33306418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study.
    Gu J; Zhang H; Xue Q; Wang L; Cheng Z; Zhang Y; Li Q; Yuan L; Li Y; Dong J; Huo Y; Tang X; Hu L; Wang X; Hua F; Shen L; Cheng J; Zhou H; Xu Y; Yang T; Wang C; Xu J; Shen J; Zhang Y; Zhang X; Hong D; Guan X; Xiao X; Wang G; Liu Y; Fu L; Chen J; Cheng X; Ding Y; Liu L; Yao Q; Zhang X; Li L; Zhang P; Deng C; Jiang C; You L; Wang K; Zhang S; Xiao J; Liu W; Du X; Shang X; Pan T; Lei C; Guo S; Zhang Z
    J Orthop Translat; 2023 Jan; 38():117-125. PubMed ID: 36381249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
    J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
    Nakamura T; Matsumoto T; Sugimoto T; Shiraki M
    Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
    Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
    Expert Opin Biol Ther; 2024 Jul; 24(7):655-663. PubMed ID: 38349618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
    Suzuki T; Nakamura Y; Kato H
    Mod Rheumatol; 2019 Jul; 29(4):676-681. PubMed ID: 30217118
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects.
    Tomaszewska-Kiecana M; Carapuça E; Florez-Igual A; Queiruga-Parada J
    Clin Transl Sci; 2024 Sep; 17(9):e70013. PubMed ID: 39206788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.